These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27268966)

  • 21. Development and optimization of dextromethorphan hydrobromide oral disintegrating tablets: effect of formulation and process variables.
    Mostafa HF; Ibrahim MA; Sakr A
    Pharm Dev Technol; 2013; 18(2):454-63. PubMed ID: 22881389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of a novel automatic disintegration apparatus for the development and evaluation of a direct compression rapidly disintegrating tablet.
    Jung HA; Augsburger LL
    Drug Dev Ind Pharm; 2012 Jul; 38(7):825-36. PubMed ID: 22091970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro characterization and mouthfeel study of functionalized calcium carbonate in orally disintegrating tablets.
    Wagner-Hattler L; Wyss K; Schoelkopf J; Huwyler J; Puchkov M
    Int J Pharm; 2017 Dec; 534(1-2):50-59. PubMed ID: 28987455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of the in vitro disintegration profile of rapidly disintegrating tablets and correlation with oral disintegration.
    Abdelbary G; Eouani C; Prinderre P; Joachim J; Reynier J; Piccerelle P
    Int J Pharm; 2005 Mar; 292(1-2):29-41. PubMed ID: 15725551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding the mechanism for paradoxical effect of ionized and unionized chitosan: Orodispersible tablets of Ondansetron Hydrochloride.
    Goel H; Vora N; Tiwary AK; Rana V
    Pharm Dev Technol; 2009; 14(5):476-84. PubMed ID: 19241220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of general multilevel factorial design with formulation of fast disintegrating tablets containing croscaremellose sodium and Disintequick MCC-25.
    Solaiman A; Suliman AS; Shinde S; Naz S; Elkordy AA
    Int J Pharm; 2016 Mar; 501(1-2):87-95. PubMed ID: 26827922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of pediatric orally disintegrating mini-tablets containing atomoxetine hydrochloride-β-cyclodextrin inclusion complex using experimental design.
    Özyılmaz ED; Comoglu T
    Drug Dev Ind Pharm; 2022 Nov; 48(11):667-681. PubMed ID: 36454038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a new disintegration method for orally disintegrating tablets.
    Kakutani R; Muro H; Makino T
    Chem Pharm Bull (Tokyo); 2010 Jul; 58(7):885-90. PubMed ID: 20606331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of Prosolv and Prosolv:Mannitol 200 direct compression fillers on the physicomechanical properties of atorvastatin oral dispersible tablets.
    Gowda V; Pabari RM; Kelly JG; Ramtoola Z
    Pharm Dev Technol; 2015 Jun; 20(4):394-400. PubMed ID: 24397821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the disintegration time of rapidly disintegrating tablets via a novel method utilizing a CCD camera.
    Morita Y; Tsushima Y; Yasui M; Termoz R; Ajioka J; Takayama K
    Chem Pharm Bull (Tokyo); 2002 Sep; 50(9):1181-6. PubMed ID: 12237533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation and evaluation of swelling induced-orally disintegrating tablets by microwave irradiation.
    Sano S; Iwao Y; Kimura S; Itai S
    Int J Pharm; 2011 Sep; 416(1):252-9. PubMed ID: 21763765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The practical approach to the evaluation of methods used to determine the disintegration time of orally disintegrating tablets (ODTs).
    Brniak W; Jachowicz R; Pelka P
    Saudi Pharm J; 2015 Sep; 23(4):437-43. PubMed ID: 27134547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formulation studies for mirtazapine orally disintegrating tablets.
    Yıldız S; Aytekin E; Yavuz B; Bozdağ Pehlivan S; Ünlü N
    Drug Dev Ind Pharm; 2016; 42(6):1008-17. PubMed ID: 26530146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conceptualisation, Development, Fabrication and In Vivo Validation of a Novel Disintegration Tester for Orally Disintegrating Tablets.
    Koner JS; Rajabi-Siahboomi AR; Missaghi S; Kirby D; Perrie Y; Ahmed J; Mohammed AR
    Sci Rep; 2019 Aug; 9(1):12467. PubMed ID: 31462654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risperidone oral disintegrating mini-tablets: A robust-product for pediatrics.
    El-Say KM; Ahmed TA; Abdelbary MF; Ali BE; Aljaeid BM; Zidan AS
    Acta Pharm; 2015 Dec; 65(4):365-82. PubMed ID: 26677895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Justification of disintegration testing beyond current FDA criteria using in vitro and in silico models.
    Uebbing L; Klumpp L; Webster GK; Löbenberg R
    Drug Des Devel Ther; 2017; 11():1163-1174. PubMed ID: 28442890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pharmaceutical study on chlorzoxazone orodispersible tablets: formulation, in-vitro and in-vivo evaluation.
    Moqbel HA; ElMeshad AN; El-Nabarawi MA
    Drug Deliv; 2016 Oct; 23(8):2998-3007. PubMed ID: 26828616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges and emerging solutions in the development of compressed orally disintegrating tablets.
    Al-Khattawi A; Mohammed AR
    Expert Opin Drug Discov; 2014 Oct; 9(10):1109-20. PubMed ID: 25045997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the ease of taking mini-tablets compared with other tablet formulations in healthy volunteers.
    Hayakawa Y; Uchida S; Namiki N
    Eur J Pharm Sci; 2016 Mar; 84():157-61. PubMed ID: 26739235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A New Test Unit for Disintegration End-Point Determination of Orodispersible Films.
    Low A; Kok SL; Khong YM; Chan SY; Gokhale R
    J Pharm Sci; 2015 Nov; 104(11):3893-903. PubMed ID: 26296236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.